StockData
Accustem Sciences Inc. logo

Accustem Sciences Inc. (ACUT) company profile

ACUTOTCPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Aug 14, 2026Score 4/30
$0.15+0.00 (0.00%)

Close on Oct 16, 2026Market cap $2.37MP/E –Yield –

About Accustem Sciences

Pharmaceutical Preparations, SIC 2834

AccuStem Sciences, Inc. is a clinical-stage diagnostics company that develops and commercializes genomic tests to assist decision-making across oncology care. Its proprietary test pipeline includes the MicroRNA Signature Classifier, a 24-microRNA blood-based assay designed to determine whether lung nodules identified through low-dose computed tomography screening are benign or malignant. The company also develops StemPrintER, a 20-gene prognostic assay measuring tumor stemness to evaluate the risk of distant recurrence in patients diagnosed with early-stage, luminal breast cancer. Additionally, it plans to provide ancillary testing services such as hereditary genetic and somatic mutation panels.

The business targets its initial commercialization activities within the United States. To support test processing, transfer, and reporting under clinical laboratory standards, the company collaborates with a partner commercial laboratory based in Lake Forest, California. AccuStem Sciences maintains its principal executive offices in New York, New York.

Summary of the business section of Accustem Sciences's latest annual report, written by StockData.

Company profile

Company

Legal name
Accustem Sciences Inc.
Headquarters
New York, NY
Address
5 Penn Plaza, 19th Floor, #1954 10001
Phone
442070661000
Employees
4, Dec 31, 2025
Industry
Pharmaceutical Preparations
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
Mercurius & Associates LLP, New Delhi, India

Stock & identifiers

Ticker
ACUT
Exchange
OTC
IPO date
Mar 3, 2022
Shares outstanding
16M, Aug 14, 2026
Public float
$9.68M, Jun 30, 2025
Filer category
Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
SEC CIK
1850767
FIGI
BBG015QPWHC7
Share class FIGI
BBG015QPWJ60
EIN
00-0000000

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Gabriele M. CerroneDirector6,502,400

Employees

Headcount reported in annual reports

“As of December 31, 2025, we had four full time employees.”

Corporate history

Events identified from SEC filings

DateEventDetails
Mar 31, 2026Late filingNotification of late filing
May 15, 2025Late filingNotification of late filing
Mar 31, 2025Late filingNotification of late filing
Jan 2, 2025Auditor changeChange in certifying accountant (8-K Item 4.01)
Dec 30, 2024Auditor changeChange in certifying accountant (8-K Item 4.01)
Nov 14, 2024Late filingNotification of late filing
Aug 14, 2024Late filingNotification of late filing
May 15, 2024Late filingNotification of late filing
Apr 10, 2024Auditor changeChange in certifying accountant (8-K Item 4.01)
May 17, 2022Late filingNotification of late filing
Mar 31, 2022Late filingNotification of late filing
Dec 3, 2021Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Jul 1, 2021Name changeName changed from AccuStem Sciences Ltd to Accustem Sciences Inc.

See a number that looks wrong?